Hepatic fibrosis is a pathological process characterized by an imbalance between the deposition and degradation of extracellular matrix components.This process is initiated by chronic liver injuries resulting from vir...Hepatic fibrosis is a pathological process characterized by an imbalance between the deposition and degradation of extracellular matrix components.This process is initiated by chronic liver injuries resulting from viral infections,alcoholic liver disease,non-alcoholic fatty liver disease,and autoimmune-mediated hepatic damage.If left untreated,hepatic fibrosis can progress to life-threatening conditions such as cirrhosis and hepatocellular carcinoma.Central to the development of fibrosis is the transdifferentiation of quiescent hepatic stellate cells(HSCs)into proliferative and fibrogenic myofibroblast-like activated HSCs(aHSCs),which play a crucial role in extracellular matrix accumulation and fibrotic tissue formation.Beyond resmetirom,a recently Food and Drug Administrationapproved medication for liver fibrosis and nonalcoholic steatohepatitis,there are currently no other established pharmacological treatments available to slow down the progression of these conditions.Moreover,activation of HSCs and formation of hepatic fibrosis have been considered irreversible.Recent studies reported transforming growth factor beta as one of the key regulators of HSCs activation and pathogenesis of hepatic fibrosis.It has been also reported that the features of aHSCs can be reversed to those of quiescent HSCs by modulating transforming growth factor beta mediated pathways.The potential of extracellular vesicles(EVs)as cell free therapeutics to treat hepatic fibrosis has been suggested earlier.However,detailed knowledge of the mechanisms involved in the alleviation of hepatic fibrosis using EVs from mesenchymal stem cells is still lacking.Hence,this review aims to describe the pathogenesis of hepatic fibrosis from the cellular and molecular point of views and shed light on the potential of EVs from mesenchymal stem cells in reversing the properties of aHSCs to their quiescent state.展开更多
Corni fructus(CF),the fruit of Cornus officinalis,is widely used in traditional Chinese medicine.This study investigated the effects of CF extract and Atorvastatin(AS)on obesity-related disorders.Twenty-five mice were...Corni fructus(CF),the fruit of Cornus officinalis,is widely used in traditional Chinese medicine.This study investigated the effects of CF extract and Atorvastatin(AS)on obesity-related disorders.Twenty-five mice were initially divided into two groups:a normal diet and a high-fat diet(HFD)group.After developing obesity,the HFD group was split into four subgroups:continued HFD,HFD with CF(400 mg/kg BW),HFD with CF(400 mg/kg BW)and AS(3 mg/kg BW),and HFD with AS(3 mg/kg BW).After six weeks of treatment,biochemical parameters were measured in each group(n=5).The mRNA expression of tumor necrosis factor-alpha(TNF-α),peroxisome proliferator-activated receptor gamma(PPAR-γ),monocyte chemoattractant protein-1(MCP-1),and glucose transporter 4(GLUT-4)was also analyzed.The molecular docking of the fruit-derived compounds was also performed with TNFα,PPAR-γ,MCP-1,GLUT4,and HMG-CoA reductase.The individual administration of CF and AS in obese mice significantly(p<0.05)reduced body weight,abdominal fat,liver weight,triglyceride,and cholesterol levels.Co-administration of CF and AS resulted in more pronounced effects.Most importantly,CF treatment significantly lowered triglyceride and low-density lipoprotein levels,while significantly increasing high-density lipoprotein levels in HFD-treated mice(p<0.05).Furthermore,the CF extract significantly(p<0.05)reduced aspartate aminotransferase and alkaline phosphatase levels in AS+HFD-treated mice.Consistent with these biochemical findings,a notable decrease in the mRNA expression of the studied genes was observed.These findings suggested that the combined use of CF with AS may substantially reduce obesity-related metabolic disorders.展开更多
摘要Hepatic fibrosis is a pathological process characterized by an imbalance between the deposition and degradation of extracellular matrix components.This process is initiated by chronic liver injuries resulting from viral infections,alcoholic liver disease,non-alcoholic fatty liver disease,and autoimmune-mediated hepatic damage.If left untreated,hepatic fibrosis can progress to life-threatening conditions such as cirrhosis and hepatocellular carcinoma.Central to the development of fibrosis is the transdifferentiation of quiescent hepatic stellate cells(HSCs)into proliferative and fibrogenic myofibroblast-like activated HSCs(aHSCs),which play a crucial role in extracellular matrix accumulation and fibrotic tissue formation.Beyond resmetirom,a recently Food and Drug Administrationapproved medication for liver fibrosis and nonalcoholic steatohepatitis,there are currently no other established pharmacological treatments available to slow down the progression of these conditions.Moreover,activation of HSCs and formation of hepatic fibrosis have been considered irreversible.Recent studies reported transforming growth factor beta as one of the key regulators of HSCs activation and pathogenesis of hepatic fibrosis.It has been also reported that the features of aHSCs can be reversed to those of quiescent HSCs by modulating transforming growth factor beta mediated pathways.The potential of extracellular vesicles(EVs)as cell free therapeutics to treat hepatic fibrosis has been suggested earlier.However,detailed knowledge of the mechanisms involved in the alleviation of hepatic fibrosis using EVs from mesenchymal stem cells is still lacking.Hence,this review aims to describe the pathogenesis of hepatic fibrosis from the cellular and molecular point of views and shed light on the potential of EVs from mesenchymal stem cells in reversing the properties of aHSCs to their quiescent state.
基金funded by the Research Cell of Noakhali Science and Technology University,Bangladesh.
摘要Corni fructus(CF),the fruit of Cornus officinalis,is widely used in traditional Chinese medicine.This study investigated the effects of CF extract and Atorvastatin(AS)on obesity-related disorders.Twenty-five mice were initially divided into two groups:a normal diet and a high-fat diet(HFD)group.After developing obesity,the HFD group was split into four subgroups:continued HFD,HFD with CF(400 mg/kg BW),HFD with CF(400 mg/kg BW)and AS(3 mg/kg BW),and HFD with AS(3 mg/kg BW).After six weeks of treatment,biochemical parameters were measured in each group(n=5).The mRNA expression of tumor necrosis factor-alpha(TNF-α),peroxisome proliferator-activated receptor gamma(PPAR-γ),monocyte chemoattractant protein-1(MCP-1),and glucose transporter 4(GLUT-4)was also analyzed.The molecular docking of the fruit-derived compounds was also performed with TNFα,PPAR-γ,MCP-1,GLUT4,and HMG-CoA reductase.The individual administration of CF and AS in obese mice significantly(p<0.05)reduced body weight,abdominal fat,liver weight,triglyceride,and cholesterol levels.Co-administration of CF and AS resulted in more pronounced effects.Most importantly,CF treatment significantly lowered triglyceride and low-density lipoprotein levels,while significantly increasing high-density lipoprotein levels in HFD-treated mice(p<0.05).Furthermore,the CF extract significantly(p<0.05)reduced aspartate aminotransferase and alkaline phosphatase levels in AS+HFD-treated mice.Consistent with these biochemical findings,a notable decrease in the mRNA expression of the studied genes was observed.These findings suggested that the combined use of CF with AS may substantially reduce obesity-related metabolic disorders.